Ticker LaunchReverse merger · Completed · QTTB
Q32 Bio Inc.
Reverse merger with Homology Medicines, Inc.
Q32 Bio Inc. merged into Homology Medicines, Inc., a Nasdaq-listed biotech whose legacy assets were to be disposed for CVR holders, in a reverse merger that takes the private company public. The deal was announced on Nov 16, 2023 and closed on Mar 25, 2024. The combined company trades as Q32 Bio Inc. (QTTB) on Nasdaq.
Q32 Bio is a clinical-stage biotechnology company developing biologic therapeutics to restore immune homeostasis. Its lead program bempikibart is in Phase 2 trials for atopic dermatitis and alopecia areata, and ADX-097 is entering a Phase 2 renal basket trial in complement disorders.
- Status
- Completed
- Private company
- Q32 Bio Inc.
- Public company
- Homology Medicines, Inc.
- Public company business before
- Nasdaq-listed biotech whose legacy assets were to be disposed for CVR holders
- Announced
- Nov 16, 2023
- Closed
- Mar 25, 2024
- Combined company
- Q32 Bio Inc. (QTTB)
- Exchange
- Nasdaq
- Sector
- Biotech & pharma
More on this deal for subscribers
- Concurrent financing and investors
- Contingent value rights (CVR)
- Reverse stock split
- Analyst notes from the filings
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Closing 8-K Mar 27, 2024
- Closing press release
- Merger agreement 8-K Nov 16, 2023
- All filings on EDGAR CIK 1661998
Other completed reverse mergers
- Trawsfynydd Therapeutics, Inc.into Onconova Therapeutics, Inc. · Apr 1, 2024
- VinHMS Pte. Ltd.into Vemanti Group, Inc. · Apr 1, 2024
- Serina Therapeutics, Inc.into AgeX Therapeutics, Inc. · Mar 26, 2024
- LENZ Therapeutics (LENZ OpCo)into Graphite Bio, Inc. · Mar 21, 2024
- Emergent Health Corp.into Resonate Blends, Inc. · Mar 14, 2024
- XTI Aircraft Companyinto Inpixon · Mar 12, 2024